UCAD alone exhibited higher positive rates (69.8%, P < .05), and addition of UCAD to AFP(>200 μ g/μL) identified 84.2% surgical‐eligible hepatocellular carcinomas, including 52.9%, 85.7%, and 88.5% hepatocellular carcinomas with size less than 3 cm (Figure 4A), size between 3 and 5 cm, and tumor larger than 5 cm, respectively, which is significantly higher than that of AFP alone at cut‐off 200 ng/mL (29.4%, 42.8%, and 57.7%, respectively). Here, AFP is linked to hepatocellular carcinoma.